Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-10
2007-04-10
Zucker, Paul A. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
10442284
ABSTRACT:
The present invention relates to a pharmaceutical composition comprising a dual Peroxisome Proliferator-Activated Receptor-alpha/Peroxisome Proliferator-Activated Receptor-gama activator (PPAR-α/PPAR-γ) and a Glucagon Like Peptide-1 (GLP-1) derivative for treating, preventing and reducing the risk of developing Type 2 diabetes, insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.
REFERENCES:
patent: 6150413 (2000-11-01), Bernardon et al.
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6214820 (2001-04-01), Jeppesen et al.
patent: 0551035 (1993-07-01), None
patent: 0879814 (1998-11-01), None
patent: 0903343 (1999-03-01), None
patent: WO 94/01420 (1994-01-01), None
patent: WO 95/03313 (1995-02-01), None
patent: WO 96/04260 (1996-02-01), None
patent: WO 96/04261 (1996-02-01), None
patent: WO 97/25042 (1997-07-01), None
patent: WO 97/36579 (1997-10-01), None
patent: WO 99/08501 (1999-02-01), None
patent: WO 99/16758 (1999-04-01), None
patent: WO 99/19313 (1999-04-01), None
patent: WO 99/20614 (1999-04-01), None
patent: WO 99/38850 (1999-08-01), None
patent: WO 99/43705 (1999-10-01), None
Bury Paul Stanley
Jeppesen Lone
Mogensen John Patrick
Pettersson Ingrid
Sauerberg Per
Began Marc A.
Green Reza
Novo Nordisk A S
Wilk-Orescar Rosemarie R.
Zucker Paul A.
LandOfFree
Combination therapy using a dual PPAR-α/PPAR-γ... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy using a dual PPAR-α/PPAR-γ..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy using a dual PPAR-α/PPAR-γ... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3735394